Microbot Medical Inc. Receives FDA 510(k) Clearance for LIBERTY® Endovascular Robotic System Commercialization
Microbot Medical Inc., a developer and manufacturer of advanced medical technologies, has announced a significant milestone with the recent FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. The clearance, which was granted on September 8, 2025, allows for the commercialization of the innovative system in the United States. This development is poised to redefine the peripheral endovascular space. The company's CEO, Harel Gadot, will discuss the significance of this approval and the company's commercialization strategy in an upcoming interview on Benzinga All Access Live on September 24, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533614-en) on September 23, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。